SCHEDULE: Driehaus Capital Discloses 4.68% Stake in Apogee Therapeutics
Beneficial Ownership Disclosure
Driehaus Capital Management LLC has reported a 4.68% beneficial ownership stake in Apogee Therapeutics, Inc., holding 2,158,502 shares of common stock.
Summary
- Driehaus Capital Management LLC, an investment adviser, filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Apogee Therapeutics, Inc.
- The filing discloses ownership of 2,158,502 shares of Apogee Therapeutics' Common Stock.
- This stake represents 4.68% of the total class of securities.
- Driehaus Capital Management LLC holds shared voting power and shared dispositive power over all 2,158,502 shares.
- The securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of Apogee Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of beneficial ownership. It doesn't contain positive or negative operational news, but the presence of an institutional investor can be seen as a minor positive signal.
Positives
- A significant institutional investor, Driehaus Capital Management LLC, has disclosed a substantial stake in Apogee Therapeutics, potentially signaling confidence in the company's prospects.
Future Outlook
NA
Industry Context
Schedule 13G filings are routine disclosures by institutional investors, such as Driehaus Capital Management LLC, when they acquire more than 5% (or in this case, close to 5% for certain filers) of a company's voting stock, or when their ownership changes significantly. This type of filing indicates a passive investment intent, meaning the investor does not seek to control or influence the management of Apogee Therapeutics, Inc. It provides transparency to the market regarding significant institutional holdings.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which could influence market perception and trading activity.
- Management: Awareness of a substantial passive investor on the shareholder register.
Key Dates
| Date | Description |
|---|---|
| 2025-09-30 | Date of event which requires filing of this statement |
| 2025-11-14 | Signature date of the filing |
Keywords
Apogee Therapeutics, Driehaus Capital Management, Schedule 13G, beneficial ownership, common stock, investment adviser, institutional ownership, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.